Phase 2 Study of Elranatamab After Idecabtagene Vicleucel in Adults with Relapsed or Refractory Multiple Myeloma

What this Trial Is About

Researchers are evaluating elranatamab, a type of antibody drug, to see if it can reduce the risk of disease worsening after treatment with idecabtagene vicleucel in adults with relapsed and refractory multiple myeloma who have already undergone four or more prior treatments. This open-label phase II study involves patients who have received idecabtagene vicleucel as standard care and achieved at least a partial response. Participants will receive elranatamab through subcutaneous injections given on specific days within 28-day cycles during Cycle 1 on Days 1, 4, 8, 15, and 22 Cycle 2 on Days 1, 8, 15, and 22 and Cycles 3 to 6 on Days 1 and 15. Treatment may continue for up to six months or until disease progression or start of another myeloma therapy. During the study, participants will attend regular visits for assessments including disease evaluations and safety monitoring. Researchers will measure outcomes such as complete response rates, progression-free survival, adverse events, overall survival, and minimal residual disease status over multiple years. Participants will be followed as long as they remain in the study or until disease progression or other myeloma treatments begin, with evaluations planned up to five years.

Elranatamab in R/R Multiple Myeloma